Related Experiment Video
Updated: Jun 26, 2025

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
Protective effects of 2,4-dinitrophenol in okadaic acid-induced cellular model of Alzheimer's disease
Susana Cardoso1, Cristina Carvalho1, Sónia C Correia1
1CNC-UC - Center for Neuroscience and Cell Biology, University of Coimbra, 3004-504 Coimbra, Portugal; CIBB - Center for Innovative Biomedicine and Biotechnology, University of Coimbra, 3004-504 Coimbra, Portugal; IIIU - Institute for Interdisciplinary Research, University of Coimbra, 3030-789 Coimbra, Portugal.
Abstract:
Alzheimer's disease (AD) research started several decades ago and despite the many efforts employed to develop new treatments or approaches to slow and/or revert disease progression, AD treatment remains an unsolved issue. Knowing that mitochondria loss of function is a central hub for many AD-associated pathophysiological processes, there has been renewed interest in exploring mitochondria as targets for intervention. In this perspective, the present study was aimed to investigate the possible beneficial effects of 2,4 dinitrophenol (DNP), a mitochondrial uncoupler agent, in an in vitro model of AD. Retinoic acid-induced differentiated SH-SY5Y cells were incubated with okadaic acid (OA), a neurotoxin often used as an AD experimental model, and/or with DNP. OA caused a decrease in neuronal cells viability, induced multiple mitochondrial anomalies including increased levels of reactive oxygen species, decreased bioenergetics and mitochondria content markers, and an altered mitochondria morphology. OA-treated cells also presented increased lipid peroxidation levels, and overactivation of tau related kinases (GSK3β, ERK1/2 and AMPK) alongside with a significant augment in tau protein phosphorylation levels. Interestingly, DNP co-treatment ameliorated and rescued OA-induced detrimental effects not only on mitochondria but also but also reinstated signaling pathways homeostasis and ameliorated tau pathology. Overall, our results show for the first time that DNP has the potential to preserve mitochondria homeostasis under a toxic insult, like OA exposure, as well as to reestablish cellular signaling homeostasis. These observations foster the idea that DNP, as a mitochondrial modulator, might represent a new avenue for treatment of AD.
Insights
2,4-dinitrophenol (DNP) may offer a new Alzheimer's disease (AD) treatment. This study shows DNP preserves mitochondrial function and restores cellular balance in an in vitro AD model, suggesting potential therapeutic benefits.
Area of Science:
- Neuroscience
- Mitochondrial Biology
- Pharmacology
Background:
- Alzheimer's disease (AD) treatment remains a significant challenge despite extensive research.
- Mitochondrial dysfunction is a key factor in AD pathogenesis, prompting interest in mitochondria-targeted therapies.
Purpose of the Study:
- To investigate the potential therapeutic effects of 2,4-dinitrophenol (DNP), a mitochondrial uncoupler, in an in vitro model of Alzheimer's disease.
Main Methods:
- SH-SY5Y cells were differentiated and exposed to okadaic acid (OA) to model AD, with or without co-treatment with DNP.
- Evaluated neuronal viability, mitochondrial function (ROS levels, bioenergetics, morphology), lipid peroxidation, and tau protein phosphorylation.
Main Results:
- OA exposure induced neuronal cell death, mitochondrial dysfunction, increased oxidative stress, and tau hyperphosphorylation.
- DNP co-treatment significantly ameliorated OA-induced mitochondrial damage and cellular dysfunction.
- DNP also restored signaling pathway homeostasis and reduced tau pathology in the AD model.
Conclusions:
- DNP demonstrates potential in preserving mitochondrial homeostasis against toxic insults relevant to AD.
- DNP may represent a novel therapeutic strategy for Alzheimer's disease by modulating mitochondrial function and cellular signaling.
More Related Videos
Related Concept Videos
Alzheimer's Disease: Treatment
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

